Attitudes of psychedelic users regarding cost of treatment and non-hallucinogenic alternatives
Bibliographic Data
| ID | 4696004 |
|---|---|
| Authors | Jacob S Aday (0000-0003-0578-8530, University of Michigan, corresponding author), Kevin F Boehnke (0000-0003-3696-3979, University of Michigan), Moss Herberholz (0009-0007-6717-7088), D J Kruger (0000-0002-2757-7016, Jacobs (United States)) |
| Year | 2024 |
| Publication date | 2024-05-30 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Journal of Psychedelic Studies (JOURNAL) |
| Journal identifiers | ISSN: 2559-9283 • E-ISSN: 2559-9283 |
| Publisher | Akademiai Kiado Zrt (PUBLISHER) |
| DOI | 10.1556/2054.2024.00354 |
| OpenAlex | W4399172660 |
| Language | EN |
| Citations received | 1 |
| References cited | 5 |
Background and aimsPsychedelic-assisted psychotherapy (PAP) is currently being studied as a possible treatment option for multiple disorders. Despite promising safety and efficacy findings, the high costs of the current PAP model makes it questionable if the treatment will be scalable. Non-hallucinogenic psychedelic analogs have been developed as a potential cost-effective alternative, but it is unclear what psychedelic users perceive as a reasonable cost for treatment and whether they would be open to trying a non-hallucinogenic analog.MethodsWe queried a large sample of people using psychedelics naturalistically (N = 1,221) about their attitudes regarding the role of altered states of consciousness in PAP outcomes, costs of treatment, and their openness to trying a non-hallucinogenic psychedelic analog for treating a mental health condition.ResultsWe found that most (76%) participants considered altered states of consciousness as very or extremely important to the therapeutic effects of psychedelics. Despite this, most (61%) were also moderately, very, or extremely likely to try a non-hallucinogenic substance if given the chance. Lastly, participants considered approximately $70-80 per hour to be a reasonable cost for various aspects of psychedelic services (e.g., preparation, integration, and dosing sessions).ConclusionsParticipants valued the role of altered states of consciousness in therapeutic changes attributed to psychedelics, but were still open to trying a non-hallucinogenic analog. Notably, the price participants considered to be a reasonable amount for PAP is well below current market projections. Future research is needed to address limitations of the study as well as to identify ways of lowering treatment costs
Consciousness · Euphoriant · Hallucinogen · Lysergic acid diethylamide · Openness to experience · Psilocybin · Psychiatry · Psychotherapist · Medicine · Neurotransmitter Receptor Influence on Behavior · Psychedelics and Drug Studies · Psychology · Social Psychology
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression
Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness
MDMA-assisted therapy for severe PTSD
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
How Do I Learn More About this?”
| Citations per year | 1 |
|---|---|
| Citation span | 2025 - 2025 (1) |
| Highly cited | No |